Rhenman & Partners Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-300,000	Closed	-$951K	–	86
2023 Q3	$951K	Hold	300,000	–	–	0.1%	82
2023 Q2	$1.49M	Hold	300,000	–	–	0.16%	78
2023 Q1	$1.49M	Sell	300,000 -40,000	-12%	-$257K	0.16%	81
2022 Q4	$2.14M	Hold	340,000	–	–	0.22%	81
2022 Q3	$3.5M	Sell	340,000 -10,000	-3%	-$136K	0.37%	73
2022 Q2	$3.99M	Buy	+350,000	New	+$3.11M	0.45%	60

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Rhenman & Partners Asset Management's ALLO Position: Q4 2023 in Review

Rhenman & Partners Asset Management sold out of Allogene Therapeutics (ALLO) in Q4 2023, closing a stake of 300,000 shares — an estimated $951K sold.

Rhenman & Partners Asset Management first reported a position in ALLO in Q2 2022 and held it in 6 quarters. The position peaked at $3.99M in Q2 2022. 170 funds tracked by Wall St. Rank hold ALLO as of Q4 2023.

Rhenman & Partners Asset Management reported no remaining Allogene Therapeutics position as of Q4 2023 after selling out during the quarter.
Rhenman & Partners Asset Management sold 300,000 Allogene Therapeutics shares in Q4 2023, an estimated $951K.
Rhenman & Partners Asset Management first reported a position in Allogene Therapeutics in Q2 2022 and held it in 6 quarters.
Rhenman & Partners Asset Management's Allogene Therapeutics position peaked at $3.99M in Q2 2022.
170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2023.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.